Cisplatin + nintedanib + pemetrexed + placebo
WebThis study enrolled 87 participants with chemo-naïve unresectable MPM, ECOG performance status 0–1, and non-sarcomatoid disease histology. Patients were randomized 1:1, double blinded, to cisplatin/pemetrexed with nintedanib 200 mg b.d. or placebo, and nintedanib or placebo was subsequently continued as monotherapy until progression. WebThe pemetrexed-cisplatin chemotherapy is standard of care in first-line (FL) treatment of malignant pleural mesothelioma (MPM). The second-line (SL) c…
Cisplatin + nintedanib + pemetrexed + placebo
Did you know?
WebMay 16, 2013 · This randomized, double-blinded study evaluated nintedanib – a triple angiokinase inhibitor – plus pemetrexed compared to pemetrexed plus placebo in patients with advanced non-squamous NSCLC not responding to, or who progressed after, first-line chemotherapy. 20 LUME-Lung 2 did not pass the pre-defined interim futility analysis from ... WebThe intervention group received up to six cycles of pemetrexed and cisplatin plus nintedanib 200 mg twice daily while the control group received chemotherapy plus …
WebThe intervention group received up to six cycles of pemetrexed and cisplatin plus nintedanib 200 mg twice daily while the control group received chemotherapy plus placebo. Nintedanib and placebo were continued until disease progression. The primary end point was PFS. Eighty-seven patients were randomly assigned 1:1 ratio. WebThis is a phase II/III confirmatory study designed to evaluate the safety and efficacy of nintedanib (BIBF 1120) in combination + (pemetrexed / cisplatin) followed by …
WebNintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, …
WebSep 11, 2024 · Treatment with pemetrexed and cisplatin and either nintedanib or matching placebo was given in 21-day courses. …
WebDec 19, 2016 · ITT analysis of the primary end point showed that treatment with nintedanib plus pemetrexed resulted in a significant prolongation of PFS compared with placebo plus pemetrexed (4.4 vs. 3.6 months with a HR of 0.83 and a p value of 0.04). dye blue flash lensWebApr 1, 2024 · Request PDF On Apr 1, 2024, Antoinette J. Wozniak and others published Short report of a phase II trial of nintedanib in recurrent malignant pleural mesothelioma (MPM) Find, read and cite all ... crystal palace under 14 football trialsWebJun 5, 2024 · Nintedanib Chemo Combo Promising for Malignant Mesothelioma Frontline treatment with nintedanib plus pemetrexed and cisplatin improved progression-free … dye bombsWebJul 1, 2024 · Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double … crystal palace t-shirtWebPatients were randomly assigned in a 1:1 ratio to receive nintedanib or placebo. Randomization was stratified by histology (epithelioid or biphasic). Treatment with … d yearsWebDec 9, 2024 · Scagliotti GV, et al. Nintedanib in Combination with Pemetrexed and Cisplatin for Chemotherapy-Naive Patients with Advanced Malignant Pleural … crystal palace v arsenal h2hWebMar 27, 2024 · For unresectable MPM, a regimen of pemetrexed (Pem) and cisplatin (Cis) was approved as the standard of care in first-line treatment by the FDA in 2004 . Currently, numerous studies are being conducted to explore the efficacy of novel agents and regimens for MPM first-line treatment. ... Regardless, any kind of therapy other than placebo may … dye blue navy hair